Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry. Issue 2 (23rd November 2022)

• Record Type: Journal Article
• Authors: Glintborg, Bente; Jensen, Dorte Vendelbo; Terslev, Lene; Hendricks, Oliver; Østergaard, Mikkel; Horskjær Rasmussen, Simon; Jensen, Mogens Pfeiffer; Adelsten, Thomas; Colic, Ada; Danebod, Kamilla; Kildemand, Malene; Loft, Anne Gitte; Munk, Heidi Lausten; Pedersen, Jens Kristian; Østgård, René Drage; Møller Sørensen, Christian; Krogh, Niels Steen; Agerbo, Jette; Ziegler, Connie; Hetland, Merete Lund
• Is Part Of: RMD open. Volume 8:Issue 2(2022)
• Publication Date: 2022-11-23
• Subjects: Patient Reported Outcome Measures -- Epidemiology -- Health services research; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2022-002549
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Aims: In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs. Methods: All patients followed in DANBIO were informed about DANBIO-from-home by electronic invitations or when attending their clinic. Characteristics of patients who did/did not use DANBIO-from-home in the period after implementation were explored by multivariable logistic regression analyses including demographic and clinical variables (gender, age group, diagnosis, disease duration, use of biological disease-modifying agent (bDMARD), Health Assessment Questionnaire (HAQ), Patient Acceptable Symptom Scale (PASS)). Time from launch to first entry was presented as cumulative incidence curves by age group (<40/40–60/61–80/>80 years). Results: Of 33 776 patients, 68% entered PROs using DANBIO-from-home at least once. Median (IQR) time to first entry was 27 (11–152) days. Factors associated with data entry in multivariate analyses (OR (95% CI)) were: female gender (1.19 (1.12 to 1.27)), bDMARD treatment (1.41 (1.33 to 1.50)), age 40–60 years (1.79 (1.63 to 1.97)), 61–80 years (1.87 (1.70 to 2.07), or age >80 years (0.57 (0.50 to 0.65)) (reference: age <40 years), lower HAQ (0.68 (0.65 to 0.71)) and PASS 'no' (1.09 (1.02 to 1.17). Diagnosis was not associated. Time to first entry of PROs was longest in patients <40 years of age (119 (24–184) days) and shortest in the 61–80 years age group (25 (8–139) days). Conclusion: A nationwide online platform for PRO in rheumatology achieved widespread use. Higher age, male gender, conventional treatment and disability were associated with no use.